Continued Fallout from Macchiarini Misconduct

The sacked researcher and surgeon was not properly vetted by the Swedish institutions that hired him in 2010, according to an independent review panel.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

PIXABAY, DEBORABALVESThe swath of destruction caused by the alleged misconduct and fraud of surgeon Paolo Macchiarini continues to widen, as an independent panel reviews his case. In a report released last week (August 31), investigators commissioned by the Karolinska University Hospital—where Macchiarini used to work—stated that both the hospital and the Karolinska Institute (KI) failed to heed warning signs that the artificial organ researcher’s skill and professionalism was not up to par with the reputation he had cultivated in the popular press.

“Macchiarini was recruited as a senior physician at the hospital even though there were strongly critical opinions from his previous employers,” the investigators wrote. “Group thinking, bandwagon effects, a very competitive care environment, many informal leaders and deficient knowledge of and respect for rules are some of the factors that may have contributed to the course of events.”

Two KI officials are suffering backlash from the Macchiarini case. Anders Hamsten, who had already resigned from the institute’s vice-chancellor position over his role in hiring Macchiarini, and Harriet Wallberg, who was president of KI when the surgeon was hired, were both dismissed from the panel that awards Nobel Prizes for Medicine, according to The Guardian. In addition, Wallberg was fired from her post as the chancellor ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies